Prioritising RWE for Impact Moving Beyond “More Studies” to Higher-Value Evidence
4:00 pm - Thursday 11th February 2027
- Rethink how RWE projects are prioritised to focus limited resources on evidence that can meaningfully influence strategic, clinical, market access and business decisions
- Shift from volume to value by identifying when fewer, more strategically focused studies can generate stronger evidence and deliver greater impact across the product lifecycle
- Build the case for earlier RWE investment by demonstrating how evidence generated earlier in development can strengthen the value proposition and inform critical decisions before launch
